Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company

Novo Nordisk A/S (NYSE:NVS) announced Thursday that it will advance subcutaneous and oral amycretin into phase 3 development in weight management.

Amycretin is developed for subcutaneous and oral administration.

The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management.

Novo Nordisk plans to initiate a phase 3 development program with amycretin for adults with overweight or obesity during the first quarter of 2026.

Also Read: Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies

Oral Amycretin Phase 1 trial evaluated the single-ascending dose and multiple-ascending doses for oral amycretin, up to 2 times ...